Adempas riociguat: Phase IIb discontinued

Bayer discontinued the double-blind, placebo-controlled, international Phase IIb RISE-IIP trial in 147 patients after the study’s IDMC observed that patients receiving Adempas

Read the full 221 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE